NCT03998176View on ClinicalTrials.gov

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE

PHASE4CompletedINTERVENTIONAL

Enrollment

43

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

October 1, 2021

Study Completion Date

April 1, 2022

Conditions

HIV-1-infection

Interventions

DRUG

Bictegravir/emtricitabine/tenofovir alafenamide

B/F/TAF single tablet formulation

Trial Locations (1)

68198

Unversity of Nebraska Medical Center, Omaha

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

University of Nebraska

OTHER